# Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

> **NCT02370706** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** PIM447
- **DRUG:** Ruxolitinib
- **DRUG:** LEE011

## Key facts

- **NCT ID:** NCT02370706
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-21
- **Primary completion:** 2020-11-09
- **Final completion:** 2020-11-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370706, "Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02370706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*